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Abstract
Katrina McClatchey is a 2004 graduate of the University of Oklahoma College of Law. Ms.
McClatchey wrote this eBrief under the direction of Professor Drew Kershen while working on
the Project on Intellectual Property Rights in Living Matter. Below, Ms. McClatchey discusses
recent and significant decisions in the European Patent Office (EPO) regarding an animal-related
invention known as the “Onco-mouse” and provides guidance on how the exception to
patentability for “animal varieties” under European Patent Convention (EPC) Article 53(b) has
been interpreted and implemented with respect to animal-related inventions.
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I.

Introduction

For biotechnological inventors of living-inventions, Article 53(b) is a particularly
interesting provision of the European Patent Convention (EPC). Article 53(b) provides that
“European patents shall not be granted in respect of… plant or animal varieties or essentially
biological processes for the production of plants or animals; this provision does not apply to
microbiological processes or the products thereof.” 1 This e-brief discusses recent and significant
decisions in the European Patent Office (EPO) regarding an animal-related invention known as
the “Onco-mouse” and provides guidance on how the exception to patentability for “animal
varieties” under Article 53(b) has been interpreted and implemented with respect to animalrelated inventions.

1

The European Patent Convention (also known as the Convention on the Grant of European Patents), Oct. 5, 1973,
as amended by the act revising art. 63 EPC of Dec. 17, 1991 and by decisions of the Administrative Council of the
European Patent Organisation of Dec. 21, 1978, Dec. 13, 1994, Oct. 20, 1995, Dec. 5, 1996 and Dec. 10, 1998, art.
53(b) http://www.european-patent-office.org/legal/epc/e/ma1.html#CVN (last visited Feb. 20, 2004) [hereinafter
EPC].
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II.

Background

Inventors of the Onco-mouse invention filed a European patent application entitled
“Method for producing transgenic animals,” 2 claiming it was a method for producing a
transgenic mammalian animal having an introduced oncogene sequence 3 –as well as the
transgenic animal itself. 4 Transgenic animals (particularly mice 5 ), which had been genetically
manipulated to have the oncogene sequence, were more likely to develop neoplasms (tumors),
and thus could be utilized in experiments for cancer research.
III.

Initial Examination

The Examining Division of the EPO 6 denied the grant of a European patent for the Oncomouse application. One of its main objections was raised against the claims to animals per se
under Article 53(b), namely the “animal varieties” exception to patentability. The Examining
Division interpreted the provision of Article 53(b) that “European patents shall not be granted in
respect of… animal varieties” as referring not only to cases where a specifically designated
variety was claimed, but also to cases where varieties were covered by a claim. 7 It reasoned that

2

European Patent Application No. 85 304 490.7 (filed June 24, 1985).
For example, method claim 1 read as follows:
1. A method for producing a transgenic non-human mammalian animal having an increased probability of
developing neoplasms, said method comprising introducing an activated oncogene sequence into a nonhuman mammalian animal at a stage no later than the 8-cell stage. Id.
4
For example, product claim 17 (for a mammal) and claim 18 (more specifically for a rodent), read as follows:
17. A transgenic non-human mammalian animal whose germ cells and somatic cells contain an activated
oncogene sequence introduced into said animal, or an ancestor of said animal, at a stage no later than the 8cell stage, said oncogene optionally being further defined according to any one of Claims 3 to 10.
18. An animal as claimed in Claim 17 which is a rodent. Id.
5
Although the patent application was directed to all mammals in general, the disclosure primarily described the use
of oncogene sequences in mice. Thus, the invention was referred to as the “Onco-mouse”.
6
The Examining Divisions of the European Patent Office is responsible for the examination of European patent
applications; see EPC, supra note 1, art. 18, http://www.european-patent-office.org/legal/epc/e/ma1.html#CVN.
7
HARVARD/Onco-mouse, [1990] E.P.O.R. 4, 7.
3
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the legislator's intention was not the exclusion of some particular group of animals, but rather the
exclusion of animals in general. 8
IV.

Appeal to the Technical Board of Appeals

Harvard appealed the Examining Division’s decision to the Technical Board of Appeals
of the EPO. 9

The Technical Board addressed the Examining Division’s interpretation and

application of the “animal varieties” exception of Article 53(b) to the Onco-Mouse patent
application. It ultimately found the Examining Division’s rejection unjustified.
In determining the scope of Article 53(b), the Technical Board first addressed the
different terminology found in the three official texts of the EPC, which are written in German,
English, and French. The English version of Article 53(b) excludes “animal varieties”. The
German version of Article 53(b) excludes “Tierarten”. The French version excludes “races
animals”. Within these different languages, the terms have differing scopes. The German term
“Tierarten” (animal species) is broader than the English term “animal varieties” and the French
term “races animales” (animal races). 10
Because it found that all three texts were equally authentic under the EPC, the Technical
Board reasoned that there was a need to establish a common meaning as to the extent that
animals are excluded from patentability under Article 53(b). 11 Although the Technical Board
ultimately concluded that “[i]t [was] now the task of the European Patent Office to find a
solution to the problem of the interpretation of Article 53(b) EPC with regard to the concept of
‘animal varieties’”, it did not accept the interpretation of the Examining Division that Article

8

Id.
The Technical Board of Appeals is responsible for the examination of appeals from the decisions of the Examining
Divisions; see EPC, supra note 1, art. 21, http://www.european-patent-office.org/legal/epc/e/ma1.html#CVN.
10
HARVARD/Onco-mouse (T19/90), [1990] E.P.O.R. 501, 509-10.
11
Id. at 510.
9
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53(b) excluded not only certain groups of animals from patentability, but in fact animals in
general. 12
The Technical Board noted that any exception to patentability under the EPC must be
“narrowly construed”. 13 The Technical Board further dismissed the possibility that the reference
to certain categories of animals in Article 53(b), rather than to animals as such, was simply a
mistake by the legislators, because nothing in the legislative history supported such an
assumption. 14

Rather, the Technical Board concluded that use of the terms “animal varieties”,

“races animals” and “Tierarten” was a “clear indication” that Article 53(b) was not intended to
cover animals as such. 15

Furthermore, the Technical Board noted that Article 53(b) also

contained in the same first half-sentence of the provision, a reference to “animals” (in general)
with regard to essentially biological processes. 16

Thus the Technical Board reasoned that

because of its use of the different terms “animal varieties” (“races animals”, “Tierarten”) and
“animals” (“animaux”, “Tiere”) in this way, the EPC legislator could not have meant “animals”
in both cases. 17
Therefore, the Technical Board found that the Examining Division was wrong in refusing
the Onco-mouse application on the ground that Article 53(b) excludes the patenting of animals as
such. The Technical Board held that “[t]he proper issue to be considered is, therefore, whether
or not the subject-matter of the application is an ‘animal variety’ (‘race animale’, ‘Tierart’)
within the meaning of Article 53(b) EPC.” The Technical Board then remitted the case back to
the Examining Division for further prosecution. It instructed the Examining Division to “first

12

Id.
Id.
14
Id.
15
Id.
16
Id.
17
Id.
13
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consider whether the subject-matter of the present application constitutes an ‘animal variety’,
‘race animale’ or ‘Tierart’ within the meaning of that provision. If it came to the conclusion that
the subject-matter [was] not covered by any of these three terms, then Article 53(b) EPC would
constitute no bar to patentability. If, however, it considered that any of these terms applie[d],
then refusal of the application would only be justified if that specific term represents the proper
interpretation of Article 53(b).” 18
V.

Re-examination by the Examining Division

After the case was remitted for further examination, the Examining Division considered
whether the term “animal variety” or its counterparts (“race animale” and “Tierart”) covered the
subject-matter of the Onco-mouse application, which was generically drafted to claim
“mammals” and “rodents”. The Examining Division avoided specifically interpreting the scope
of the term “animal varieties” by concluding that “[a]lthough the term ‘animal variety’ [was] not
entirely clear, in particular in view of the differing wording in the three equally binding
languages of the EPC, it nevertheless could be stated with certainty that rodents, or even
mammals, constituted a taxonomic classification unit much higher than species (‘Tierart’). An
‘animal variety’ or ‘race animale’ is a sub-unit of a species and therefore of even lower ranking
than a species.”

19

Accordingly, the Examining Division found that the subject-matter of the

claims to animals per se in the Onco-mouse application were not covered by the three terms of
Article 53(b) of the EPC. 20

18

Id. at 511.
HARVARD/Onco-mouse, [1991] E.P.O.R. 525, 526.
20
Id.
19
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VI.

Proceedings in the Opposition Division

Ultimately, a European Patent was granted for the Onco-mouse application. 21 However,
the Onco-mouse patent faced further scrutiny in the Opposition Division22 of the EPO. Several
oppositions challenging the validity of the Onco-mouse patent were filed. Again, one of the
main arguments raised by the opponents pertained to the patentability of animals under Article
53(b).
In addressing the patentability of animals in accordance with Article 53(b), the
Opposition Division first reviewed recent developments in the Implementing Rules of the EPC,
as well as in relevant case law. The Opposition Division first referred to Rule 23c(b) 23 , which
stipulates that inventions concerning plants and animals are patentable if the technical feasibility
of the invention is not confined to a particular plant or animal variety. 24
The Opposition Division next noted that while appeals decisions addressing the issue of
patentability of animals did not exist outside the Onco-mouse case, the decision from the
Technical Board of Appeals did contain several legal considerations highly relevant to the
present issue with regard to Article 53(b). 25

First, exceptions to patentability have to be

construed narrowly. 26 Secondly, the appearance of “animals” (in general) and “animal varieties”
in the same half-sentence of Article 53(b) is a clear indication that the legislator did not intend

21

European Patent No. 169672 (issued May 13, 1992).
The Opposition Division of the EPO is responsible for the examination of oppositions against any European
patent filed by third parties challenging the validity of the granting of the patent; see EPC, supra note 1, art, 19, 99100, available at http://www.european-patent-office.org/legal/epc/e/ma1.html#CVN.
23
Implementing Regulations to the Convention on the Grant of European Patents, Dec. 13, 2001, Rule 23c(b),
http://www.european-patent-office.org/legal/epc/e/ma2.html#REG (last visited Feb. 20, 2004) [hereinafter
Implementing Regulations]. Rule 23c(b) provides: “Biotechnological inventions shall also be patentable if they
concern… plants or animals if the technical feasibility of the invention is not confined to a particular plant or animal
variety.”
24
Onco-mouse/HARVARD, OJ EPO 10/2003 – Decisions of the Opposition Division, at 497, para. 8.1.1.
http://www.european-patent-office.org/epo/pubs/oj003/10_03/10_4733.pdf (last visited Apr. 12, 2004).
25
Id. at 498, para. 8.1.2.
26
Id.
22
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the term “animal varieties” to cover animals in general or that the legislator meant “animals” in
both cases. 27 Finally, if the subject-matter of the claims is not covered by any of the three terms
“animal variety”, “race animale”, or “Tierart”, then Article 53(b) constitutes no bar to
patentability. 28

The Opposition Board also noted that a recent decision relating to the

patentability of plants under Article 53(b) had held that “[a] claim wherein specific plant
varieties are not individually claimed is not excluded from patentability under Article 53(b) EPC
even though it may embrace plant varieties.” 29
In light of these recent rules and case law, the Opposition Division concluded that
“[l]iving matter and in particular plants and animals are accessible to patent protection.” 30 It
found this to apply not only to process protection but also product protection. 31 The Opposition
Division also concluded that, as already established for plants under Rule 23c(b), if a grouping is
characterized by a specific gene and not by its whole genome, then it is not excluded from
patentability as a “variety”. 32

In applying its conclusions to the Onco-mouse patent, the

Opposition Division noted that “[t]here is no doubt that the invention as claimed is applicable to
more than just varieties of mice… Therefore, the argument that the patent relates to particular
mouse strains and therefore to animal varieties which are not patentable under Article 53(b) EPC
must fail. The feasibility of the invention is not confined to a particular animal variety in the
meaning of Rule 23c(b) EPC.” 33

27

Id.
Id.
29
Id. at 498, para. 8.1.3 (citing Novartis/Transgenic Plant decision, (G01/98) [2000] E.P.O.R. 303).
30
Onco-mouse/HARVARD, supra note 24, at 499, para. 8.2.1.
31
Id.
32
Id.
33
Id. at 499, para. 8.2.2.
28
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The Opposition Division also disagreed with the argument that it was the legislator's
intention in Article 53(b) to not allow patents on animals in general. The Opposition Division
first examined the applicability of case law which determined that, as far as plant varieties were
concerned, the purpose of Article 53(b) was to comply with the ban on dual protection under a
plant varieties protection scheme known as the International Union for the Protection of New
Varieties of Plants (UPOV) Convention 34 . The Opposition Division noted that the purpose in
also excluding animal varieties was not clear since no equivalent protection was available at that
time, or at present, for animal varieties as products of animal breeding.35 However, it concluded
that most obvious reason for this was that there was an intention to create, or at least keep open
the possibility to create, such a law for the protection of animal varieties later on. 36

The

Opposition Division found that if the legislator had in mind a different purpose for the exclusion
of animal varieties than that for plant varieties, then the legislator would have had to make this
very clear by using appropriate language in the EPC. 37 Since the legislator had not done so, the
Opposition Division concluded that “[t]he equal linguistic treatment of plant and animal varieties
in these bodies of law [was] a clear indication that the purpose of the exclusions must have been
the same for both.” 38 Furthermore, the Opposition Division reasoned that because of the use of
the different notions “animals” and “animal varieties” in the same half-sentence of Article 53(b),

34

International Convention for the Protection of New Varieties of Plants, Dec. 2, 1961, 33 U.S.T. 2703, 815
U.N.T.S. 89, as Revised at Geneva on Nov. 10, 1972, on Oct. 23, 1978, and on Mar. 19, 1991,
http://www.upov.int/en/publications/conventions/1991/act1991.htm#_14 (last visited Feb. 26, 2004).
35
Onco-mouse/HARVARD, supra note 24, at 499, para. 8.2.3.
36
Id.
37
Id.
38
Id.
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the clear wording of the article itself indicated that its exclusion was limited to varieties only,
and did not extend to animals in general. 39
Because it had found that the technical feasibility of the Onco-mouse invention was not
confined to a particular animal variety, and that exclusion for “animal varieties” under Article
53(b) did not extend to animals in general, the Opposition Division ultimately held that Article
53(b) of the EPC did not constitute a bar to patentability for the subject matter claimed in the
Onco-mouse patent. 40 , 41
VII.

Conclusion

In accordance with the Onco-mouse line of decisions, an inventor of an animal-related
invention should consider the following:
•
•
•

•
•

The exception for “animal varieties” under Article 53(b) of the EPC does
not exclude animals in general from patentability.
Inventions concerning plants and animals are patentable if the technical
feasibility of the invention is not confined to a particular animal variety.
The exclusion from patentability for animals under Article 53(b) is defined
by the terms used within the three official texts of the EPC, which includes
“animal varieties” (in English), “race animale” (in French) or “Tierart” (in
German).
Claims drafted to cover a taxonomic classification unit higher than species
(“Tierart”), or the lower ranking subunits of animal variety or animal race
(“race animales”), would not fall with the exclusion of Article 53(b).
Interpretations EPC provisions and rules established with regard to plants
may also be applicable with regard to animals since the equal linguistic
treatment of plant and animal varieties in Article 53(b) indicates that the
purpose of the exclusion is the same for both bodies of law.

In view of these guidelines, biotechnologists seeking protection in Europe under a
European patent for animal-related inventions should not be apprehensive of the Article 53(b)

39

Id. at 500, para. 8.2.5.
Id. at 500, para. 8.3.
41
On July 6, 2004, the Technical Board of Appeal further restricted the Onco-mouse patent to apply only to mice,
rather than the broader category, i.e. rodents, applicable before the decision. See EPO – Press Release, European
Patent Office at http://www.european-patent-office.org/news/pressrel/2004_07_06_e.htm.
40

9

2 OKLA. J. L. & TECH. 22 (2004)
www.okjolt.org
prohibition on “animal varieties”. As a practical matter, the application of the “animal varieties”
exception appears to be strictly limited to animal-related inventions with subject matter claiming
a specific animal variety. Thus, even with the “animal varieties” exception to patentability under
Article 53(b), the European patent remains a viable option for biotechnologists with animalrelated inventions.
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